News

Seemal R. Desai, MD, and Pearl E. Grimes, MD, discuss the complexities of colorism and its impact on pigmentary disorders.

In this Q&A, Christopher Brooks, MD, discusses advancing research on intralymphatic immunotherapy for environmental and, more recently, food allergies.

The NDA submission follows positive results from the CALIBRATE phase 3 trial, which evaluated encaleret versus standard-of-care in adults with ADH1.

Mitapivat has been submitted to the FDA for accelerated approval in sickle cell disease after phase 3 results showed a hemoglobin benefit.

Sameh Sayfo, MD, discusses his recent analysis of the DETOUR2 study, highlighting the efficacy of the DETOUR system for patients regardless of runoff.

New OX40 biologics aim for longer atopic dermatitis control, but Kaposi's sarcoma concerns split experts as amlitelimab advances and rocatinlimab halts.

Findings suggest potential value in complete blood count (CBC)-derived parameters for assessments of hidradenitis suppurativa (HS) disease activity and severity.

Experts weigh in on a rapidly evolving treatment landscape, from a first-line oral option to a one-time CRISPR therapy showing 87% attack reduction.

Catch up on the hematology news and data you missed from April 2026.

In this segment of his interview, Chovatiya speaks about how new consensus definitions on atopic dermatitis disease activity could impact clinical trials.

In recognition of Food Allergy Awareness Month, Brooks discusses food challenges, omalizumab, oral immunotherapy, and persistent gaps in food allergy management.

Saseen discusses the current dyslipidemia treatment landscape, highlighting current challenges and potential paths forward.

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

This FDA News Month in Review provides a round-up of regulatory decisions from April 2026.

Fukami, MD, discusses how first-line ESD may offer both survival and cost advantages over esophagectomy for EEC in the United States.

This episode covers recent advancements in treating type 1 diabetes, including the Tandem AID system for pregnant women and teplizumab for adolescents.

Chedid, MD, MS, explains the evolving therapeutic IBD landscape, including new data from DDW 2026.

Chedid describes the future of personalizing IBD care based on patient characteristics.

Ahmad Masri, MD, from OHSU, discusses the positive topline results from this phase 3 trial, highlighting a new path forward for nHCM.

Noureddin discusses HU6’s mitochondrial uncoupling mechanism and why muscle preservation may become increasingly important in MASH care.

Catch up on updates in viral hepatitis treatment, advances in rare liver disease care, and more.

Catch up on new IBD drug trial data, regulatory actions, and updates in IBS in this April month in review.

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

Juanita Mora, MD, discusses The American Lung Association's 2026 report, elucidating a disproportionate burden on people of color.

Patient education may be the missing piece needed to bridge the gap between hypertension treatments and improved outcomes.

Early data suggest varenicline may improve abdominal pain, bloating, and bowel symptoms in patients with IBS.

In 38 patients with house dust mite allergy, 18 months of SLIT was linked to early expansion and later reduction of allergen-specific type 2 memory B cells.

Colombel discusses long-term LUCENT extension data showing durable clinical, endoscopic, and histologic outcomes with mirikizumab in moderately to severely active UC.